News

This content was published in the EU4MD update released on 30.09.2021. This update also presents a section on partnerships, announcements, studies, upcoming events, and a research corner. Focus on: Methamphetamine from Afghanistan...

This report was prepared before recent developments in Afghanistan and before the withdrawal of US military and other NATO allies from the country. The findings of this report are preliminary and will...

A two-year work programme on bilateral cooperation with Georgia was agreed upon today at the first advisory committee meeting of the EMCDDA4Georgia project, hosted virtually by the agency. Launched on 3 May...

Six steps to help improve the quality of drug services and systems in Europe are presented today in a new manual from the EU drugs agency (EMCDDA) . Entitled Implementing quality standards...

It was with great sadness that the EMCDDA learned today of the passing of His Excellency Dr Jorge Sampaio, former President of the Portuguese Republic. Dr Jorge Sampaio was a highly-esteemed friend...

Synthetic cannabinoids come under the spotlight today in a new report released by the EU drugs agency (EMCDDA) . Widely available across Europe and highly potent, these substances are placing some users...

Recent EMCDDA studies on the impact of COVID-19 containment measures on drug services in Europe highlighted the rapid and widespread adoption of telemedicine and online communication. In some countries, core drug treatment...

How many people die every year in Europe from a drug-related death? Are women and men affected equally? What substances are involved in these fatalities? These are some of the questions answered...

On World Hepatitis Day , the EU drugs agency (EMCDDA) is launching a new set of resources to help European countries meet health targets to eliminate viral hepatitis. The resources, presented in...

In May 2021, a multidisciplinary committee established by the French Parliament published three reports on cannabis regulation . The reports, totalling 450 pages, address the regulation and impact of three types of...

It was with great sadness that the EMCDDA learned this week of the passing of its long-term friend and colleague Tomáš Zábranský MD, PhD. Dr Zábranský was a highly-esteemed Czech epidemiologist, who...

Contingency Management – evidence continues to build-up, time to start talking about implementation? According to the just published EMCDDA European Drug Report cocaine is the second most commonly used illicit drug in...

This content was published in the EU4MD update released on 30.06.2021. This update also presents a section on partnerships, annoucements, studies, upcoming events, and a research corner. Focus on: European Drug Report...

Current insights and future challenges on drugs and prison in Europe are explored today in a major new study published by the EU drugs agency (EMCDDA) ( 1 ). Released on the...

The Council of the EU (Foreign Affairs) approved on 21 June the EU Drugs Action Plan for 2021–2025 . The new plan presents the concrete actions needed to achieve the priorities of...

Resilience, agility and innovation are among the recurring themes in the latest EMCDDA General Report of Activities , released today. The annual publication — presenting key achievements and governance — relates how...

Today, the EU drugs agency (EMCDDA) publishes its European Drug Report 2021: Trends and Developments , the latest annual review of the drug situation in Europe ( 1 ). Based on data...

New benzodiazepines, which are not controlled by international drug laws, come under the spotlight today in a new report released by the EU drugs agency (EMCDDA) ( 1 ). Often marketed as...

Since early 2020, the COVID-19 pandemic has had a dramatic impact on the way in which we live. Countries in Europe, and around the world, have had to introduce unprecedented measures to...

The new EU Drugs Strategy 2021–25 makes explicit that the European response to drugs should be evidence-based and delivered through a balanced and integrated approach, which ultimately must be judged on its...